Dr. Michael Pearl Discusses Palliative Care

Video

Dr. Michael Pearl breaks down the differences between palliative care and hospice care and explains the New York Palliative Care Information Act in this recording of his recent webinar, “Palliative Care for Women with Cancer.” Dr. Pearl is Professor and Director of the Division of Gynecologic Oncology in the Department of Obstetrics, Gynecology and Reproductive Medicine at Stony Brook University Hospital. Watch it below.

SHARE Webinar: Palliative Care for Women with Cancer from SHARE on Vimeo.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Photo of a woman with blonde hair wearing a denim jacket in front of a blue background
2 experts are featured in this series.
2 experts are featured in this series.
Photo of a woman with brown hair and a floral blouse
Photo of a woman with a blue border around the image
2 experts are featured in this series.
2 experts are featured in this series.
Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
Related Content
Image of an ovary with a tumor

INX-315 Receives FDA Fast Track Status for CCNE1-Amplified Ovarian Cancer

Bridget Hoyt
April 30th 2025
Article

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ovarian cancer.

The Vitals

What New Cancer Drugs Were Approved in 2023?

Lindsay Fischer
January 1st 2024
Podcast

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

Graphic reading "FDA Approved" resembling a stamp of approval

Ready-to-Dilute Thiotepa Approved for Breast and Ovarian Adenocarcinomas

Bridget Hoyt
April 29th 2025
Article

A ready-to-dilute formulation of thiotepa has been approved by the FDA for use in breast and ovarian cancers.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Photo of a young woman shaking hands with a healthcare provider in a doctor's office

Opinion: Increasing Support and Awareness for AYAs With Cancer

Hayley Feuchs, LMSW
April 28th 2025
Article

AYA Cancer Awareness Month offers an opportunity for nurses to go further in supporting AYAs with cancer.

Image of red blood cells

FDA Declines Breakthrough Status, Halts Itolizumab’s Path Forward in Acute GVHD

Roman Fabbricatore
April 27th 2025
Article

The FDA’s decision not to grant breakthrough designation or accelerated approval for itolizumab in acute GVHD has led to the discontinuation of the pivotal phase 3 EQUATOR trial.